v 1

Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts.

Usp39 PROTAC-V1 is a highly efficient PROTAC degrader targeting the splicing protein USP39, which primarily degrades intracellular USP39 via selective proteasomal degradation.

Epsilon-V1-2, a Cys-conjugated, is a biologically active peptide known as the εPKC-specific inhibitor. It hampers εPKC functionality by obstructing its translocation and the phosphorylation of MARCKS, additionally perturbing εPKC's interaction with its anchoring protein, εRACK. The peptide includes a cysteine residue at its C-terminus, facilitating the formation of potential disulfide bonds with carrier proteins. Pyroglutamyl formation can occur spontaneously at the N-terminus if glutamine or glutamic acid is present, enhancing peptide stability against gastrointestinal proteases. Pyroglutamyl peptides, a recognized subset, are accounted for in the peptide's purity during HPLC analysis.

V1 iridoid is a useful organic compound for research related to life sciences and the catalog number is T124032.

Xanthone V1a is a useful organic compound for research related to life sciences and the catalog number is T126501.

Terlipressin Acetate, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.

V1a/V2 antagonist 1 (Compound 18j) is an orally active dual-target antagonist of V1a and V2 receptors, exhibiting high binding affinity toward these receptors [Ki values are hV1a: 0.13 nM, hV2: 0.53 nM, and mV1a: 0.5 nM; IC50 for hV1a is 2.2 nM]. This compound can inhibit oxytocin-induced scratching behavior in mice.

V1b receptor antagonist-1 is a potent and selective vasopressin 1b (V1b) receptor antagonist capable of crossing the blood-brain barrier. It exhibits antidepressant activity and is applicable in the study of neurological disorders such as depression.

UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2].

vMIP-II (1-21) (NT21MP) TFA (TFA is a potent inhibitor of CXCR4. This compound interacts broadly with CC and CXC chemokine receptors. Furthermore, vMIP-II (1-21) TFA inhibits CXCR4 by competing for binding sites with 125I-SDF-1R, exhibiting an IC50 value of 190 nM.

Myosin V-IN-1 is a potent and selective inhibitor of Myosin V with a Ki value of 6 μM.Myosin V-IN-1 inhibits actin V and slows down actin-activated myosin V ATPase by selectively inhibiting the release of ADP from the actinoglobulin complex.

αvβ1 integrin-IN-1 is a potent and selective inhibitor of αvβ1 integrin (IC50 of 0.63 nM) with antifibrotic effects.

1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist known for its anti-tumor properties.

V-ATPase-IN-1 (Compound 3b-03) is an inhibitor of Vacuolar-type H+-ATPases (V-ATPase), exhibiting an inhibition constant (IC50) of 194.80 μM and effectively targeting the V-ATPase subunit A with a dissociation constant (Kd) of 0.803 μM. This compound demonstrates insecticidal activity against M. separata (LC50 = 2.64 mM), aiding in the development of chemical insecticides.

Tubulin polymerization/V-ATPase-IN-1 (compound F10) is an inhibitor of tubulin polymerization and V-ATPase. It exhibits potent antiproliferative activity against four types of human cancer cells by inhibiting both tubulin and V-ATPase. The compound also induces apoptosis and immunogenic cell death while suppressing tumor growth in the RM-1 allograft model with enhanced T lymphocyte infiltration.

Human PD-L1 Inhibitor V is a peptide that binds to the human PD-1 protein with an affinity characterized by a dissociation constant (Kd) of 3.32 μM, effectively inhibiting the hPD-1/hPD-L1 interaction [1].

Human PD-L1 Inhibitor V TFA, a peptide that binds to the human PD-1 protein, exhibits a dissociation constant (Kd) of 3.32 μM and effectively inhibits the hPD-1/hPD-L1 interaction [1].

RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).

Gilvocarcin Vintermediate-1 (Compound 4) is an intermediate in the biosynthetic pathway of Gilvocarcin V.

αvβ1 integrin-IN-1 TFA is an effective and selective αvβ1 integrin inhibitor (IC50: 0.63 nM).

αVβ8-IN-1 is an αVβ8 integrin inhibitor that suppresses the growth of multiple tumour cell lines (EMT6, CT26, KPC, TKCC-10). It may be employed in research concerning tumours, idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and other conditions.

αvβ6-IN-1 (compound 28) is an effective orally active inhibitor of αvβ6 integrin (αvβ6integrin), with a pIC50 value of 8.1. This compound shows potential for research in idiopathic pulmonary fibrosis.

αvβ1integrin-IN-3 is a selective inhibitor of αvβ1 integrin, exhibiting antifibrotic properties.

EcDHFR/FKBP12 F36V binder-1 (compound 1) is a bifunctional molecule that integrates the domains of Escherichia coli dihydrofolate reductase (EcDHFR) and FKBP12F36V.